表紙
市場調查報告書

骨質疏鬆症治療藥的世界及中國市場:各藥物類型,各給藥途徑,各流通管道,各地區的規模,佔有率,預測,機會分析(2020年∼2027年)

Global and China Osteoporosis Drugs Market, By Drug Type, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 952843
出版日期 內容資訊 英文 180 Pages
商品交期: 2-3個工作天內
價格
骨質疏鬆症治療藥的世界及中國市場:各藥物類型,各給藥途徑,各流通管道,各地區的規模,佔有率,預測,機會分析(2020年∼2027年) Global and China Osteoporosis Drugs Market, By Drug Type, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年07月22日內容資訊: 英文 180 Pages
簡介

骨質疏鬆症,特徵是骨頭密度與骨質降低,引起手腕、腰、脊椎的骨折。骨質疏鬆症的各種要素,有遺傳要素,鈣、鎂、維他命D的低攝取,食慾不振等的飲食障礙,不活動與不動,過剩的酒精攝取等。由於骨質疏鬆症的盛行率增加,以及新的骨質疏鬆症治療藥的認證與發售的增加,在預測期間內預計大幅度促進骨質疏鬆症治療市場成長。

本報告提供骨質疏鬆症治療藥的世界及中國市場調查,市場概要,市場成長要素及阻礙因素分析,各藥物的種類、給藥途徑、流通管道、地區的市場規模的變化與預測,競爭情形,主要企業的簡介,COVID-19的影響,市場機會等系統性資訊。

目錄

第1章 調查目的、前提條件

第2章 市場展望

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場明細 :藥物的各類型
    • 市場明細 :各給藥途徑
    • 市場明細 :各流通管道
    • 市場明細 :各國
    • Coherent Opportunity Map(COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 主要的焦點
  • 產品銷售
  • PEST分析
  • 技術的進步
  • 法規方案
  • 合併和收購
  • COVID19對市場的影響

第4章 藥物的各類型:2019年∼2027年(10億美元單位)

  • 簡介
  • 雙膦酸鹽
  • 抑鈣素
  • 荷爾蒙療法
  • 選擇性雌激素受體調節(SERM)
  • 副甲狀腺素相關蛋白質(PTHrP)類比
  • RANKL抑制劑

第5章 各給藥途徑:2019年∼2027年(10億美元單位)

  • 簡介
  • 口服
  • 注射劑
  • 其他

第6章 各流通管道:2019年∼2027年(10億美元單位)

  • 簡介
  • 醫院藥局
  • 線上藥局
  • 零售藥局

第7章 各地區:2019年∼2027年(10億美元單位)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中國
  • 中東
  • 非洲

第8章 競爭情形

  • 企業簡介
    • Merck & Co.
    • Eli Lilly
    • Procter & Gamble
    • Enzo Biochem, Inc.
    • Sanofi-Aventis
    • Novartis
    • Wyeth
    • Roche
    • GlaxoSmithKline
    • UCB
    • Amgen
    • BeiGene Co., Ltd.
    • Bone Biologics
    • Teijin Pharma Limited
    • JHL Biotech Inc.
    • Keros Therapeutics
    • Taro Pharmaceuticals Inc.

第9章 Section

目錄

Osteoporosis is characterized by reduction in the density and quality of bones that often result in broken bones in the wrist, hip, and spine. Various factors responsible for osteoporosis include, genetic factors, low intake of calcium, magnesium, and vitamin D, eating disorders such as anorexia, inactivity and immobility, and excessive alcohol intake. Increasing approvals and launches of novel osteoporosis drugs along with increasing prevalence of osteoporasis is expected to significantly drive the osteoporosis treatment market growth over forecast period.

Key features of the study:

  • This report provides in-depth analysis of the Global and China Osteoporosis Drugs Market and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the Global and China Osteoporosis Drugs Market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The Global and China Osteoporosis Drugs Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global and China Osteoporosis Drugs Market

Detailed Segmentation:

  • Global and China Osteoporosis Drugs Market, By Drug Type:
    • Bisphosphonates
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Hormone Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Rank Ligand (RANKL) Inhibitor
  • Global and China Osteoporosis Drugs Market, By Route of Administration:
    • Oral
    • Injectable
    • Others
  • Global and China Osteoporosis Drugs Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Global and China Osteoporosis Drugs Market, By Region:
  • North America
    • By Drug Type:
    • Bisphosphonates
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Hormone Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Rank Ligand (RANKL) Inhibitor
    • By Route of Administration
    • Oral
    • Injectable
    • Others
    • By Distribution Channel
    • Hospitals Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • By Country
    • U.S.
    • Canada
  • Latin America
    • By Drug Type:
    • Bisphosphonates
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Hormone Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Rank Ligand (RANKL) Inhibitor
    • By Route of Administration
    • Oral
    • Injectable
    • Others
    • By Distribution Channel
    • Hospitals Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Drug Type:
    • Bisphosphonates
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Hormone Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Rank Ligand (RANKL) Inhibitor
    • By Route of Administration
    • Oral
    • Injectable
    • Others
    • By Distribution Channel
    • Hospitals Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • By Country
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Drug Type:
    • Bisphosphonates
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Hormone Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Rank Ligand (RANKL) Inhibitor
    • By Route of Administration
    • Oral
    • Injectable
    • Others
    • By Distribution Channel
    • Hospitals Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • By Country
    • Japan
    • India
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • China
    • By Drug Type:
    • Bisphosphonates
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Hormone Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Rank Ligand (RANKL) Inhibitor
    • By Route of Administration
    • Oral
    • Injectable
    • Others
    • By Distribution Channel
    • Hospitals Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Middle East
    • By Drug Type:
    • Bisphosphonates
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Hormone Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Rank Ligand (RANKL) Inhibitor
    • By Route of Administration
    • Oral
    • Injectable
    • Others
    • By Distribution Channel
    • Hospitals Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • By Country
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • By Drug Type:
    • Bisphosphonates
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Hormone Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Rank Ligand (RANKL) Inhibitor
    • By Route of Administration
    • Oral
    • Injectable
    • Others
    • By Distribution Channel
    • Hospitals Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • By Country
    • North Africa
    • Central Africa
    • South Africa
  • Company Profiles
  • Merck & Co. *
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Eli Lilly
  • Procter & Gamble
  • Enzo Biochem, Inc.
  • Sanofi-Aventis
  • Novartis
  • Wyeth
  • Roche.
  • GlaxoSmithKline
  • UCB
  • Amgen
  • BeiGene Co., Ltd.
  • Bone Biologics
  • Teijin Pharma Limited
  • JHL Biotech Inc.
  • Keros Therapeutics
  • Taro Pharmaceuticals Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Description Page= Toc Page=

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Country
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Highlights
  • Product launch
  • PEST Analysis
  • Technological Advancements
  • Regulatory Scenario
  • Mergers and Acquisitions
  • Impact of COVID19 on market

4. Global and China Osteoporosis Drugs Market, By Drug Type, 2019 - 2027, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Bisphosphonates
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
  • Calcitonin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Hormone Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Selective Estrogen Receptor Modulators (SERMs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Rank Ligand (RANKL) Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)

5. Global and China Osteoporosis Drugs Market, By Route of Administration, 2019 - 2027, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)

6. Global and China Osteoporosis Drugs Market, By Distribution Channel, 2019 - 2027, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Bn)

7. Global and China Osteoporosis Drugs Market, By Region, 2019 - 2027, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
  • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Bn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Bn)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Bn)
    • Japan
    • India
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • China
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
  • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Bn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

  • Company Profiles
    • Merck & Co.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Eli Lilly
    • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Procter & Gamble
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Enzo Biochem, Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Sanofi-Aventis
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Novartis
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Wyeth
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Roche
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • GlaxoSmithKline
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • UCB
    • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Amgen
    • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • BeiGene Co., Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Bone Biologics
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Teijin Pharma Limited
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • JHL Biotech Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Keros Therapeutics
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Taro Pharmaceuticals Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact

*Browse 28 market data tables and 18 figures on "Osteoporosis Drugs Market - Global and China forecast to 2027".